Domestic manufacturing Phamatech manufactures its own rapid testing products in the United States, presenting a compelling selling point for customers prioritizing domestic production, quality control, and faster supply chain reliability in clinical and forensic testing.

Comprehensive accreditations With SAMHSA, CAP-FDT, CLIA and ISO accreditations, Phamatech demonstrates high compliance and quality standards, which can be leveraged to target healthcare providers and labs seeking proven reliability and certifications for sensitive drug testing programs.

Integrated testing portfolio Exclusive access to U-VERIFY DNA Drug and Alcohol Testing, Countrywide Testing rapid tests, and ansa Home Health Testing positions Phamatech as a one-stop solution for clinical, forensic, and at-home testing needs, enabling cross-sell across segments.

Recent on-site COVID expansion Past initiatives to launch on-location COVID-19 PCR and antibody testing indicate capability and interest in rapid deployment services, suggesting upsell opportunities for on-site testing programs, mobile clinics, or corporate wellness partnerships.

Mid-market growth focus Revenue range and employee size suggest solid mid-market positioning with room to scale; target opportunities include expanding lab services, workflow automation, and SaaS-enabled testing solutions for mid-sized clinics, regional labs, and specialty testing centers.